Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Rhythm Biosciences Ltd. ( (AU:RHY) ) just unveiled an update.
Rhythm Biosciences has signed a 12‑month supply and distribution agreement with UK-based Digistain Limited to commercialise its geneType genetic test portfolio in Southeast Asia, starting with the Philippines as the initial launch market. The deal provides structured per-test pricing, minimum volume commitments, and renewal options, giving Rhythm a clear revenue line of sight and establishing its first contracted commercial entry into this underserved region.
By leveraging Digistain’s established cancer diagnostics networks and sub-distribution channels, including links with Precision Healthcare PTE, Rhythm gains an immediate regional footprint without building its own infrastructure. The agreement supports the company’s dual-platform and international expansion strategy, positioning geneType as a cost-effective, clinically validated risk assessment solution in a large, growing market with increasing healthcare spending and low penetration of advanced genetic testing.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.22 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Ltd is an Australian predictive cancer diagnostics technology company focused on early cancer detection through its geneType genetic test platform. The geneType portfolio offers clinically validated genetic risk assessments across nine tests covering cancer predisposition and cardio-metabolic risk, processed through the company’s NATA-accredited laboratory and partner AGRF in Melbourne. The business targets high-growth international markets where access to advanced, cost-effective genetic diagnostics is still limited.
Average Trading Volume: 1,038,208
Technical Sentiment Signal: Buy
Current Market Cap: A$67.62M
Find detailed analytics on RHY stock on TipRanks’ Stock Analysis page.